Spread Hope
with etapidi
A treatment that is designed to work with your immune system and help you live longer
Share with Us Your Condition
Non-Small Cell Lung Cancer
(NSCLC)
Clinical Study Results
In a clinical study, people who received ETAPIDI + chemotherapy and whose tumor tested positive for the biomarker PD-L1 lived longer than those who received placebo + chemotherapy
ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; NSCLC, squamous & non squamous non-small cell lung cancer; PD-L1, programmed death ligand 1.